Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Hepion Pharmaceuticals Inc
Healthcare
P/NCAV
0.45x
Ticker
HEPA
Exchange
NASDAQ
Country
United States
Close
1.46 $
Mkt Cap
5.6M $
EV
-13.7M $
NCAV Burn Rate
77.5%
Current Ratio
3.32
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.3x
EV/FCF
0.4x
Dilution
146.2% p.A
Total Net Income
-170.5M $
Cheapness
67.0%
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company-s cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average